Table 2 Regulatory roles of inflammatory factors in systemic metabolic reprogramming
From: Cancer cachexia: molecular basis and therapeutic advances
Classification | Mediators | Receptor | Major Activities | Mechanism of Action | References |
|---|---|---|---|---|---|
Interleukin family | IL1 | IL1R1, IL1R2 | Inhibit food intake; promote protein and fat decomposition; enhance IL6 expression | Promoting α-MSH release from POMC neurons; stimulating hypothalamic neurons to release CRH | |
IL4 | IL4Rα, IL13Rα, γc | Inhibit adipogenic differentiation of FAPs by insulin; prevent fatty degeneration of muscle; promote clearance of injured muscle fibers | Activating the STAT6 signaling pathway | ||
IL6 | IL6Rα, gp130 | Inhibit myofibril synthesis and stimulate muscle breakdown; promote lipolysis and browning; massive liver hypertrophy and APR; splenomegaly; neuroinflammation; cardiac dysfunction and wasting | Activating the STAT signaling pathway; increasing the expression of Atrogin1; inhibiting phosphorylation of mTOR, EIF4EBP1, and RPS6 kinases | ||
IL20 | IL22R1, IL20R2 | Loss of adipose tissue | Enhancing PD-L1 via IFN-α; promoting macrophage infiltration to adipose tissue; increasing expression of ATGL and HSL | ||
Tumor necrosis factor | TNFα | TNFR | Promote lipolysis; inhibit protein synthesis and promote muscle atrophy; weaken muscle strength | Inhibiting LPL expression; enhancing ATGL activity; activating the NF-κB signaling pathway; promoting ROS generation; activating the UPS; activating the AMPK pathway; inhibiting the PI3K/Akt pathway | |
Growth factors | TGFβ | TGFβR1, TGFβR2 | Stimulate profibrotic muscle; inhibit muscle function recovery; promote skeletal myogenesis | Reversing the IGF-1/PI3K/Akt hypertrophy pathway by inhibiting Akt phosphorylation; inducing smad2/3/4 complex; regulating skeletal muscle oxidative metabolism | |
OSM | OSMR, gp130, LIFR | Promote muscle atrophy; stimulate lipolysis and inhibit adipocyte insulin response | Activating the JAK/STAT signaling pathway; inducing amyotrophic-related genes expression; increasing EDA2R expression | ||
LIF | LIFR, gp130 | Elevate lipolysis; induction of muscle atrophy; appetite suppression | Activating JAK/STAT3, PI3K/Akt/mTOR and MAPK signaling pathways; stimulating α-MSH release; increasing leptin expression | ||
GDF15 | GFRAL, ALK1, ALK5 | Regulate vagal sympathetic nervous system, inhibit appetite; enhance ATGL-dependent sympathetic nerve activation of adipose tissue lipolysis; promote osteoclast differentiation | Activating Smad pathway, PI3K/Akt signaling pathway and NF-κB signaling387 pathway; promoting activation of RET oncogene; activating HPA axis; promoting the expression of MuRF1 and MAFbx/atrogin-1 | ||
Interferon | IFNγ | IL28Rα, IL10Rβ | Accelerate protein degradation; suppression of appetite | Activating JAK/STAT signaling pathway; promoting inflammatory response | |
Chemokines | LCN2 | MC4R, SLC22A17 | Suppress appetite; activation of immune cells; promote lipolysis | Activating cAMP and MC4R signaling in the hypothalamus; inducing the ferroptosis |